Feedback
Settings

Settings

Goto Application

214,116 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 21,412
1.WO/2025/140504T CELL RECEPTOR TARGETING POLYPEPTIDE WITH KRAS G12V MUTATION AND USE OF T CELL RECEPTOR
WO - 03.07.2025
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
 Appl.No PCT/CN2024/143046 Applicant IMMUXELL BIOTECH LTD. Inventor HU, Hong-Ming
Provided in the present invention are a T cell receptor targeting a polypeptide with a KRAS G12V mutation and the use of the T cell receptor. The T cell receptor molecule of the present invention specifically targets the KRAS G12V mutation, and the CDR3 sequence of the α chain variable region of the T cell receptor molecule contains CAVNPNTGNQFYF (SEQ ID NO: 1) or a mutant of SEQ ID NO: 1, and/or the CDR3 sequence of the β chain variable region contains CASSQDYGPQETQYF (SEQ ID NO: 2) or a mutant of SEQ ID NO: 2. Further provided in the present invention are a nucleic acid molecule encoding the T cell receptor molecule, a multivalent complex and dual-targeting protein molecule containing the T cell receptor molecule, a nucleic acid construct, a cell expressing the T cell receptor molecule, etc.
2.WO/2025/143579NOVEL PEPTIDE
WO - 03.07.2025
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
 Appl.No PCT/KR2024/018986 Applicant HYSENSBIO CO., LTD Inventor PARK, Joo Hwang
The present invention relates to a novel peptide, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide, and a pharmaceutical composition, a quasi-drug composition, and a health-functional food composition that include the peptide.
3.WO/2025/144884APOE LIPOPROTEIN MIMETICS AND METHODS OF USE THEREOF
WO - 03.07.2025
Int.Class C07K 14/775
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
775Apolipopeptides
 Appl.No PCT/US2024/061899 Applicant KISBEE THERAPEUTICS, INC. Inventor DIBELLA, Elsie
The present disclosure includes systems and compositions based on lipoproteins. The lipoprotein systems may optionally include payloads for delivery to cells, tissues, organs and/or subjects in need thereof. Methods of utilizing the lipoproteins and the lipoprotein systems are also provided herein.
4.WO/2025/140535PD-1/IL-2R BISPECIFIC ANTIBODY FUSION PROTEIN, AND USE AND USAGE METHOD THEREOF
WO - 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2024/143132 Applicant FORTVITA BIOLOGICS (SINGAPORE) PTE. LTD. Inventor ZHOU, Hui
The present invention relates to a PD-1/IL-2R bispecific antibody fusion protein for treating tumors (such as solid tumors or hematologic tumors), or a pharmaceutical composition or pharmaceutical combination containing same, and a use and usage method thereof.
5.WO/2025/143580NOVEL PEPTIDE
WO - 03.07.2025
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
 Appl.No PCT/KR2024/018987 Applicant HYSENSBIO CO., LTD Inventor PARK, Joo Hwang
The present invention relates to: a novel peptide; a polynucleotide encoding the peptide; an expression vector comprising the polynucleotide; and a pharmaceutical composition, a quasi-drug composition, and a health-functional food composition, which comprise the peptide.
6.WO/2025/137979USE OF SPECIFIC POLYPEPTIDE IN THE PREPARATION OF DRUG FOR TREATING AND PREVENTING PROSTATE CANCER
WO - 03.07.2025
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/CN2023/142593 Applicant QI'AN (GUANGZHOU) BIOTECHNOLOGY CO., LTD Inventor ZHOU, Xiaohui
Provided are the use of a specific polypeptide in the preparation of a drug for treating and preventing prostate cancer, and the use of the specific polypeptide in the preparation of an immune inducer. The specific polypeptide is derived from TRPM8 protein, and has a good effect on the treatment and prevention of prostate cancer in each stage, especially androgen-independent prostate carcinoma.
7.WO/2025/141129FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES AND THEIR USES
WO - 03.07.2025
Int.Class A61K 38/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
 Appl.No PCT/EP2024/088520 Applicant ZEALAND PHARMA A/S Inventor MELANDER, Claes
Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described. In particular, it has been found that one of the main, specified, degradation products are equally or more potent than glepaglutide and is responsible for approximately half of the loss in content of glepaglutide, in particular the degradation product that forms when the Asp residue at a position corresponding to position 33 of native human GLP-2 isomerises to form an Iso-Asp/Beta Asp residue.
8.WO/2025/142974PROPHYLACTIC AND THERAPEUTIC AGENT FOR DISEASES CAUSED BY TYPE I ALLERGIC REACTION ACCOMPANYING ADMINISTRATION OF ANTICANCER AGENT
WO - 03.07.2025
Int.Class A61K 38/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
44Oxidoreductases (1)
 Appl.No PCT/JP2024/045804 Applicant LTT BIO-PHARMA CO., LTD. Inventor MIZUSHIMA, Tohru
The present invention addresses the problem of providing a prophylactic and therapeutic agent for diseases caused by a type I allergic reaction accompanying administration of a platinum preparation and/or a taxane-based anticancer agent.　The present invention relates to a pharmaceutical composition for treating or preventing diseases caused by a type I allergic reaction accompanying administration of a platinum preparation and/or a taxane-based anticancer agent, the pharmaceutical composition containing a lecithinized superoxide dismutase.
9.WO/2025/143139AGENT CONTAINING POLYPEPTIDE COMPRISING AMINO ACID SEQUENCE CORRESPONDING TO HLA-DR-BINDING EPITOPE OF ACHR
WO - 03.07.2025
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
 Appl.No PCT/JP2024/046203 Applicant DENKA COMPANY LIMITED Inventor FUJIMORI Satoshi
Disclosed is an activator for regulatory T cells, an inhibitor of the activity of effector T cells, an inhibitor of the activation of B cells, an agent for suppressing humoral immunity, or a therapeutic agent or a prophylactic agent for an autoimmune disease, which contains a polypeptide comprising an amino acid sequence corresponding to an HLA-DR-binding epitope of an AChR.
10.WO/2025/140545NOVEL LONG-ACTING HUMAN FSH AND LH FUSION PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 03.07.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2024/143165 Applicant ZONHON BIOPHARMA INSTITUTE, INC. Inventor MA, Bruce Yong
An FSH and LH fusion protein, which is composed of a first polypeptide, a second polypeptide, a third polypeptide, and a fourth polypeptide; the first polypeptide comprises, from the N-terminus to the C-terminus: a β subunit of FSH, a β subunit of LH, a hinge, a CH2 domain, a CH3 domain, or a β subunit of LH, a β subunit of FSH, a hinge, a CH2 domain, a CH3 domain; the second polypeptide comprises, from the N-terminus to the C-terminus: a hinge, a CH2 domain, a CH3 domain; the third and fourth polypeptides are each composed of an α subunit of FSH. The FSH and LH fusion protein simultaneously possesses FSH and LH functions; at the same time, compared with recombinant or natural FSH and LH, the heterodimer has a longer half-life, can provide long-acting, mild and continuous gonadotropin supplementation, and is suitable for various FSH and LH deficiency-related diseases such as male idiopathic hypogonadotropic hypogonadism, female pituitary insufficiency, hypogonadotropic amenorrhea, or hypogonadotropic infertility. The described protein has better drug economics and better patient compliance.
# -